YU5301A - Primena derivata kamptotecina sa smanjenom gastro-intestinalnom toksičnošću - Google Patents

Primena derivata kamptotecina sa smanjenom gastro-intestinalnom toksičnošću

Info

Publication number
YU5301A
YU5301A YU5301A YU5301A YU5301A YU 5301 A YU5301 A YU 5301A YU 5301 A YU5301 A YU 5301A YU 5301 A YU5301 A YU 5301A YU 5301 A YU5301 A YU 5301A
Authority
YU
Yugoslavia
Prior art keywords
campttothecin
derivatives
gastrointestinal toxicity
reduced gastrointestinal
administered
Prior art date
Application number
YU5301A
Other languages
English (en)
Inventor
Herve Toutain
Magali Guffroy
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of YU5301A publication Critical patent/YU5301A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Primena derivata kamptotecina za proizvodnju lekova namenjenih za lečenja kancera gastro-intestinalnih puteva, koja prouzrokuje manje sekundarne gastrointestinalne efekte, naznačena time, što se rastvor natrijum-hlorida daje za vreme ili pre i za vreme davanja pomenutog leka.[The invention concerns the use of camptothecin for preparing medicines for treating cancers of the gastrointestinal tract, provoking fewer gastrointestinal side effects, characterised in that a sodium chloride solution is administered while or before said medicine is administered.
YU5301A 1998-08-05 1999-08-03 Primena derivata kamptotecina sa smanjenom gastro-intestinalnom toksičnošću YU5301A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9810043A FR2782009B1 (fr) 1998-08-05 1998-08-05 Utilisation de derives de la comptothecine, avec une toxicite gastro-intestinale reduite
US9631898P 1998-08-12 1998-08-12

Publications (1)

Publication Number Publication Date
YU5301A true YU5301A (sh) 2005-06-10

Family

ID=9529409

Family Applications (1)

Application Number Title Priority Date Filing Date
YU5301A YU5301A (sh) 1998-08-05 1999-08-03 Primena derivata kamptotecina sa smanjenom gastro-intestinalnom toksičnošću

Country Status (6)

Country Link
CN (1) CN1144592C (sh)
BR (1) BR9912765A (sh)
FR (1) FR2782009B1 (sh)
PL (1) PL345826A1 (sh)
UA (1) UA72468C2 (sh)
YU (1) YU5301A (sh)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225404A (en) * 1989-11-06 1993-07-06 New York University Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
WO1996011005A2 (en) * 1994-10-06 1996-04-18 Atlas Leon T Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases

Also Published As

Publication number Publication date
UA72468C2 (en) 2005-03-15
PL345826A1 (en) 2002-01-14
CN1144592C (zh) 2004-04-07
CN1354667A (zh) 2002-06-19
BR9912765A (pt) 2001-05-15
FR2782009A1 (fr) 2000-02-11
FR2782009B1 (fr) 2000-09-15

Similar Documents

Publication Publication Date Title
MY141584A (en) Pharmaceutical uses of bisphosphonates
BR0207378A (pt) Tratamento de câncer
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
DE69834923D1 (en) Hochgradig lipophile camptothecin-derivate
IL149147A0 (en) Use of oxcarbazepine for the manufacture of oral dosage form medicament
HU890950D0 (en) Process for decreasing the harmful side-effects of cancer therapy
BG105216A (en) Use of camptothecin derivatives , with reduced gastrointestinal toxicity
GB9920912D0 (en) Novel derivatives of flavones,xanthones and coumarins
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
MY134690A (en) Antitumor therapy comprising distamycin derivatives.
CA2369626A1 (en) Use of cell membrane penetrating indigoid bisindole derivatives
EP1208840A3 (en) Combination of fluorouracil and a methylol transfer agent for the treatment of tumor metastases and cancer
YU5301A (sh) Primena derivata kamptotecina sa smanjenom gastro-intestinalnom toksičnošću
CA2399709A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
NZ514911A (en) Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
BG106151A (en) Pharmaceutical complex
AU3274597A (en) Remedies and preventives for stomatitis
YU29803A (sh) Kombinacija kamptotekina i derivata stilbena za lečenje raka
BG106534A (en) Oral solution containing galanthamine and a sweetening agent
WO2001000240A3 (en) Antitumor compound
WO1999043332A8 (en) Antitumor combination comprising epirubicin and gemcitabine for the treatment of non-small-cell lung cancer
CA2259997A1 (en) Remedies and preventives for stomatitis
UA36163A (uk) Спосіб профілактики олігоануричної форми гострої ниркової недостатності
UA33715A (uk) Спосіб лікування залізодефіцитних анемій у вагітних